B7-mediated costimulation and the immune response

Blood Reviews

Volumn 10, Issue 2, 1996, Pages 111-127

  Schultze, J ^a   Nadler, L M ^a   Gribben, J G ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; CYTOKINE; CYTOKINE RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; AUTOIMMUNITY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CLONAL ANERGY; ETIOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SKIN DISEASE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 0030036067     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(96)90040-5     Document Type: Article

References (107)

1. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992; 356(6370): 607-609.
2. Gimmi CD, Freeman GJ, Gribben JG, Gray G, Nadler LM. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci U S A 1993; 90(14): 6586-6590.
3. Lenschow DJ, Zeng Y, Thistlethwaite JR et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA41g [see comments]. Science 1992; 257(5071): 789-79 2.
4. Turka LA, Linsley PS, Lin H et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992; 89: 11102-11105.
5. Boussiotis VA, Freeman GJ, Gray GS, Gribben JG, Nadler LM. B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance. J Exp Med 1993; 178(5): 1753-1763.
6. Freeman GJ, Freedman AS, Segil JM, Lee G, Whitman JF, Nadler LM. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol 1989; 143(8): 2714-2722.
7. Freeman GJ, Gribben JG, Boussiotis VA et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation [see comments]. Science 1993; 262(5135): 909-911.
8. Azuma M, Ito D, Yagita H et al. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 1993; 366(6450): 76-79.
9. Hart DN, Starling GC, Calder VL, Fernando NS. B7/BB-1 is a leucocyte differentiation antigen on human dendritic cells induced by activation. Immunology 1993; 79(4): 616-620.
10. Freedman AS, Freeman GJ, Rhynhart K, Nadler LM. Selective induction of B7/BB-1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway. Cell Immunol 1991; 137(2): 429-437.
11. Ding L, Linsley PS, Huang LY, Germain RN, Shevach EM. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 1993; 151(3): 1224-1234.
12. Mitra RS, Judge TA, Nestle FO, Turka LA, Nickoloff BJ. Psoriatic skin-derived dendritic cell function is inhibited by exogenous IL-10. J Immunol 1995; 154: 2668-2677.
13. Boussiotis VA, Freeman GJ, Gribben JG, Daley J, Gray G, Nadler LM. Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation. Proc Natl Acad Sci USA 1993; 90(23): 11059-11063.
14. Nickoloff B, Mitra R, Lee K et al. Discordant expression of CD28 ligands, BB1, and B7 on keratinocytes in vitro and psoriatic cells in vivo. Am J Pathol 1993; 142(4): 1029-1040.
15. Sharpe AH. Analysis of lymphocyte costimulation in vivo using transgenic and 'knockout' mice. Curr Opin Immunol 1995; 7: 389-395.
16. Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 1991; 173(3): 721-730.
17. Gimmi CD, Freeman GJ, Gribben JG et al. B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc Natl Acad Sci USA 1991; 88(15): 6575-6579.
18. June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today 1994; 15(7): 321-331.
19. Gross JA, St JT, Allison JP. The murine homologue of the T lymphocyte antigen CD28. Molecular cloning and cell surface expression. J Immunol 1990; 144(8): 3201-3210.
20. Cerdan C, Martin Y, Courcoul M et al. Prolonged IL-2 receptor alpha/CD25 expression after T cell activation via the adhesion molecules CD2 and CD28. Demonstration of combined transcriptional and post-transcriptional regulation. J Immunol 1992; 149(7): 2255-2261.
21. Freeman GJ, Boussiotis VA, Anumanthan A et al. B7-1 and B7-2 do not deliver identical costimulatory signals since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 1995; 2: 523-532.
22. Fraser JD, Weiss A. Regulation of T-cell lymphokine gene transcription by the accessory molecule CD28. Mol Cell Biol 1992; 12(10): 4357-4363.
23. de Boer M, Kasran A, Kwekkeboom J, Walter H, Vandenberghe P, Ceuppens JL. Ligation of B7 with CD28/CTLA-4 on T cells results in CD40 ligand expression, interleukin-4 secretion and efficient help for antibody production by B cells. Eur J Immunol 1993; 23(12): 3120-3125.
24. Lindsten T, Lee KP, Harris ES et al. Characterization of CTLA-4 structure and expression on human T cells. J Immunol 1993; 151(7): 3489-3499.
25. Thompson CB, Lindsten T, Ledbetter JA et al. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc Natl Acad Sci USA 1989; 86(4): 1333-1337.
26. Boise LH, Minn AJ, Noel PJ et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bel-XL. Immunity 1995; 3: 87-98.
27. Hutchcroft JE, Bierer BE. Activation-dependent phosphorylation of the T-lymphocyte surface receptor CD28 and associated proteins. Proc Nat Acad Sci USA 1994; 91: 3260-3264.
28. August A, Gibson S, Kawakami K, Kawakami T, Mills GB, Dupont B. CD28 is associated with and induces the immediate tyrosine phosphorylation and activation of the Tec family kinase ITK/EMT in the human Jurkat leukemic T-cell line. Proc Natl Acad Sci USA 1994; 91: 9347-9351.
29. Raab M, Cai YC, Bunnell SC, Heyeck SD, Berg LJ, Rudd CE. p56Lck and p59Fyn regulate CD28 binding to phosphatidylinositol 3-kinase, growth factor receptor-bound protein GRB-2, and T cell-specific protein-tyrosine kinase ITK: implications for T-cell costimulation. Proc Natl Acad Sci USA 1995; 92: 8891-8895.
30. Brunet JF, Denizot F, Luciani MF et al. A new member of the immunoglobulin superfamily - CTLA-4. Nature 1987; 328(6127): 267-270.
31. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174(3): 561-569.
32. Harper K, Balzano C, Rouvier E, Mattei MG, Luciani MF, Golstein P. CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J Immunol 1991; 147(3): 1037-1044.
33. Freeman GJ, Lombard DB, Gimmi CD et al. CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production. J Immunol 1992; 149(12): 3795-37801.
34. Schneider H, Prasad KV, Shoelson SE, Rudd CE. CTLA-4 binding to the lipid kinase phospatidylinositol 3-kinase in T cells. J Exp Med 1995; 181: 351-355.
35. Stein P, Fraser J, Weiss A. The cytoplasmic domain of CD28 is both necessary and sufficient for costimulation of IL-2 secretion and association with phosphatidylinositol 3'-kinase. Molec Cell Bio 1994; 14(5): 3392-3402.
36. Gribben JG, Freeman GJ, Boussiotis VA et al. CTLA4 mediates antigen-specific apoptosis of human T cells. Proc Natl Acad Sci USA 1995; 92: 811-815.
37. Walunas TL, Lenschow DJ, Bakker CY et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1:405-413.
38. Linsley PS, Greene JL, Tan P et al. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med 1992; 176(6): 1595-1604.
39. + T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA4. J Immunol 1995; 155: 1032-1036.
40. Krummel MF, Allison JP. CD28 and CTLA4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995; 182: 459-465.
41. Tivol EA, Boriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multi-organ tissue destruction, revealing a critical negative regulatory role for CTLA-4. Immunity 1995; 3: 541-547.
42. Waterhouse P, Penninger JM, Timms E et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995; 270: 985-988.
43. Linsley PS, Bradshaw J, Urnes M, Grosmaire L, Ledbetter JA. CD28 engagement by B7/BB-1 induces transient down-regulation of CD28 synthesis and prolonged unresponsiveness to CD28 signaling. J Immunol 1993; 150(8 Pt 1): 3161-3169.
44. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, constimulation and death. Cell 1994; 76: 959-962.
45. Boussiotis VA, Freeman GJ, Griffin JD, Gray GS, Gribben JG, Nadler LM. CD2 is involved in maintenance and reversal of human alloantigen specific clonal anergy. J Exp Med 1994; 180: 1665-1673.
46. Freeman GJ, Disteche CM, Gribben JG et al. The gene for B7, a costimulatory signal for T-cell activation, maps to chromosomal region 3q13.3-3q21. Blood 1992; 79(2): 489-494.
47. Essery G, Feldman M, Lamp J. Interleukin-2 can prevent and reverse antigen induced unresponsiveness in cloned human T lymphocytes. Immunology 1988; 64: 413-416.
48. Beverly B, Kang SM, Lenardo MJ, Schwartz RH. Reversal of in vitro T cell clonal anergy by IL-2 stimulation. Int Immunol 1992; 4(6): 661-671.
49. Schorle H, Holtschke T, Hunig T, Schimpl A, Horak I. Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature 1991; 352: 621-624.
50. Shahinian A, Pfeffer K, Lee KP et al. Differential T cell costimulatory requirements in CD28-deficient mice. Science 1993; 261(5121): 609-612.
51. Russell SM, Keegan AD, Harada N et al. Interleukin-2 receptor gamma chain: a functional component of the interleukin-4 receptor [see comments]. Science 1993; 262(5141): 1880-1883.
52. Kondo M, Takeshita T, Ishii N et al. Sharing of the interleukin-2 (IL-2) receptor γ chain between receptors for IL-2 and IL-4. Science 1993; 262: 1874-1877.
53. Noguchi M, Nakamura Y, Russel SM et al. Interleukin-2 receptor γ chain: a functional component of interleukin-7 receptor. Science 1993; 262: 1877-1880.
54. Boussiotis VA, Barber DL, Nakarai T et al. Prevention of T cell anergy by signaling through the γc chain of the IL-2 receptor. Science 1994; 266: 1039-1042.
55. Miller JF, Flavell RA. T-cell tolerance and autoimmunity in transgenic models of central and peripheral tolerance. Curr Opin Immunol 1994; 6: 892-899.
56. Guerder S, Meyerhoff J, Flavell R. The role of the T cell costimulator B7-1 in autoimmunity and the induction and maintenance of tolerance to peripheral antigen. Immunity 1994; 1: 155-166.
57. Guerder S, Picarella DE, Linsley PS, Flavell RA. Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumor necrosis factor alpha leads to autoimmunity in transgenic mice. Proc Natl Acad Sci USA 1994; 91: 5138-5142.
58. Harlan DM, Abe R, Lee KP, June CH. Potential roles of the B7 and CD28 receptor families in autoimmunity and immune evasion. Clin Immunol Immunopathol 1995; 75: 99-111.
59. Soldevila G, Geiger T, Flavell RA. Breaking immunologic ignorance to an antigenic peptide of simian virus 40 large T antigen. J Immunol 1995; 155: 5590-5600.
60. Herrath MG, Guerder S, Lewicki H, Flavell RA, Oldstone MB. Coexpression of B7-1 and viral ('self') transgenes in pancreatic beta cells can break peripheral ignorance and lead to spontanous autoimmune diabetes. Immunity 1995; 3: 727-738.
61. Simon JC, Dietrich AD, Mielke V et al. Expression of the B7/BB1 activation antigen and its ligand CD28 in T-cell-mediated skin disease. J Invest Dermatol 1994; 103: 539-543.
62. Nickoloff B, Nestle F, Zheng X, Turka L. T Lymphocytes in skin lesions of psoriasis and mycosis fungoides express B7-1: a ligand for CD28. Blood 1994; 83(9): 2580-2586.
63. Verwilghen J, Lovis R, De Boer M et al. Expression of functional B7 and CTLA4 on rheumatoid synovial0 T cells. J Immunol 1994; 153: 1378-1385.
64. Wucherpfennig KW, Hafler DA. A review of T-cell receptors in multiple sclerosis: clonal expansion and persistence of human T-cells specific for an immunodominant myelin basic protein peptide. Ann N Y Acad Sci 1995; 756: 241-258.
65. Windhagen A, Newcombe J, Dangond F et al. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med 1995; 182: 1985-1996.
66. Miller SD, Vanderlugt CL, Lenschow DJ et al. Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. Immunity 1995; 3: 739-745.
67. McRae BL, Vanderlugt CL, Dal Canto MC, Miller SD. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med 1995; 182: 75-85.
68. Kuchroo VK, Das MP, Brown JA et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995; 80: 707-718.
69. Jingwu Z, Medaer R, Hashim GA, Chin Y, van den Berg-Loonen E, Raus JC. Myelin basic protein specific T lymphocytes in mutiple sclerosis and controls: precursor frequency, fine specificty and cytotoxicity. Ann Neurol 1992; 32: 330-338.
70. Chou YK, Bourdette DN, Offner H et al. Frequency of T cells specific for myelin basic protein and myelin proteolipid 7protein in blood and cerebrospinal fluid in multiple sclerosis. J Neuroimmunol 1992; 38: 105-113.
71. Ostrand-Rosenberg S. Tumor immunotherapy: the tumor cell as antigen-presenting cell. Curr. Opin. Immunol 1994; 6(5): 722-727.
72. Dranoff G, Mulligan RC. Gene Transfer as Cancer therapy. Adv Immunol 1995; 58: 417-453.
73. Van Pel A, Van der Bruggen P, Coulie PG et al. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Reviews 1995; 145: 229-250.
74. Pardoll DM. Tumor antigens. A new look for the 1990s. Nature 1994; 369(6479): 357.
75. Boon T, Cerottini JC, Eynde B, Bruggen P, Pel AV. Tumor antigens recognized by T lymphoctyes. Ann Rev Immunol 1994; 12: 337-366.
76. Guinan EC, Gribben JG, Boussiotis VA, Freeman GJ, Nadler LM The pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 1994; 84: 3261-3282.
77. Chen L, Linsley PS, Hellstrom KE. Costimulation of T cells for tumor immunity. Immunology Today 1993; 14(10): 483-486.
78. Townsend SE, Su FW, Atherton JM, Allison JP. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Research 1994; 54(24): 6477-6483.
79. Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler LM, Freeman GJ, Glimcher LH. Constitutive expression of B7 restores immunogenicity of autologous tumor cells. Proc Natl Acad Sci USA 1993; 90: 5687-5690.
80. + cytotoxic T lymphocytes in the absence of exogenous help. J Exp Med 1993; 177(6): 1791-1796
81. . 81. Hellstrom KE, Hellstrom I, Chen L. Can co-stimulated tumor immunity be therapeutically efficacious? Immunol Reviews 1995; 145: 123-145.
82. Allison JP, Hurwitz AA, Leach DR. Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr Opin Immunol 1995; 7: 682-686.
83. Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
84. Baskar S, Glimcher L, Nabavi N, Jones RT, Ostrand-Rosenberg S. Major histocompatibility complex Class II+B7-1+tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med 1995; 181(2): 619-629.
85. + T cells in cancer immunotherapy. Curr Opin Immunol 1994; 6(5): 741-745.
86. Yang G, Hellstrom KE, Hellstrom I, Chen L. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J Immunol 1995; 154: 2794-2800.
87. Matulonis U, Dosiou C, Freeman G et al. B7-1 is superior to B7-2 constimulation in the induction and maintenance of T cell-mediated antileukemia immunity. J Immunol 1996; 156: 1126-1131.
88. Denfeld RW, Dietrich A, Wuttig C et al. In situ expression of B7 and CD28 recptor families in human maligant melanoma: relevance for T-cell mediated anti-tumor immunity. Int J Cancer 1995; 62: 259-265.
89. Munro M, Freedman A, Aster J et al. In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease. Blood 1994; 83(3): 793-798.
90. Schultze JS, Cardoso AA, Freeman GJ et al. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci USA 1995; 92: 8200-8204.
91. Croft M, Bradley LM, Swain SL. Naive versus memory CD4 T cell response to antigen: memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells. J Immunol 1994; 152(6): 2675-2685.
92. Nabavi N, Freeman GJ, Gault A, Godfrey D, Nadler LM, Glimcher LH. Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression. Nature 1992; 360(6401): 266-268.
93. Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 1993; 177(4): 925-935.
94. Banchereau J, Bazan F, Blanchard D et al. The CD40 antigen and its ligand. Ann Rev Immunol 1994; 12: 881-899.
95. Faasen AE, Dalke DP, Berton MT, Warren WD, Pierce SK. CD40-CD40 ligand interactions stimulate B cell antigen processing. Eur J Immunol 1995; 25: 3249-3255.
96. Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992; 71: 1065-1068.
97. Lanzavecchia A. Identifying strategies for immune intervention. Science 1993; 260: 937-943.
98. Melief CJM, Kast M. T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol Rev 1995; 146: 167-177.
99. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271-296.
100. Hsu FJ, Benike C, Fagnoni F et al. Vaccination of patients with B-cell lymphoma using autologous antigen pulsed dendritic cells. Nature Medicine 1996; 2: 52-58.
101. Linsley PS, Wallace PM, Johnson J et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 1992; 257(5071): 792-795.
102. Lin H, Bolling SF, Linsley PS et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4-Ig plus donor-specific transfusion. J Exp Med 1993; 178(5): 1801-1806.
103. Blazar BR, Taylor PA, Linsley PS, Vallera DA. In vivo blockade of CD28/CTLA4: By/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood 1994; 83: 3815-3825.
104. Theobald M, Nierle T, Bunjes D, Arnold R, Heimpel H. Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings. N Engl J Med 1992; 327: 1613-1617.
105. Schwarer AP, Jiang YZ, Brookes PA et al. Frequency of anti-recipient alloreactive helper T-cell precursors in donor blood and graft-versus-host disease after HLA-identical sibling bone-marrow transplantation. Lancet 1993; 341: 203-205.
106. Gribben JG, Guinan EC, Boussiotis VA et al. Complete blockade of B7 mediated costimulation is necessary to induce human alloantigen specific anergy: a method to ameliorate graft versus host disease and extend the donor pool. Blood; in press.
107. Ferrara JLM, Deeg HJ. Mechanisms of disease. Graft-versus-host disease. N Engl J Med 1991; 324: 667-674.